HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


National Advertising Division In Brief

This article was originally published in The Tan Sheet

Executive Summary

P&G spurs review of ACT mouthwash claims: The National Advertising Division advises Sanofi-Aventis' Chattem business to modify and discontinue certain claims about ACT Total Care rinse. The Council of Better Business Bureaus division, acting on a complaint filed by Procter & Gamble, examined claims that ACT is "the mouthwash that does it all," "fights unsightly plaque (as part of a dentist-approved oral health program)," provides "total care," "strong teeth + healthy mouth + fresh breath" and "kills bad breath germs." At the start of the inquiry, Chattem said it would discontinue use of the "fights unsightly plaque," "does it all" and "total care" claims. NAD determined that Chattem's lab testing alone was insufficient to support the claim that the product kills bad breath, or similar claims, including "kills germs to freshen breath" because it does not reflect germ kill when the product is used by a person as intended. The CBBB unit also questioned whether the phrase "healthy mouth" conveyed a greater health benefit than supported by the evidence, and recommended modifying the claim to state "strong teeth + fresh breath = healthy mouth" or a similar iteration. P&G, which markets the Scope and Crest mouthwash and tooth whitener lines, also argued that "Total Care" in the Chattem product name constituted an unsupported claim. But NAD disagreed, saying "there is no evidence in the record indicating consumer confusion as to the name." NAD added that it is generally "reluctant" to recommend product name changes and "does not make this recommendation lightly and only does so after due consideration of the issues." Chattem said it accepted the board's findings, although it disagreed that its study alone was insufficient to support the claim that the product kills bad breath germs

You may also be interested in...

New Products In Brief

Buckwheat honey sweetens cough/cold category: Jeffrey L. Chamberlain, a physician in Grand Rapids, Mich., and his wife Christine introduce an alternative to pediatric cough/cold medications. Honey, Don't Cough Children's Buckwheat Honey sells for a suggested retail price of $4.99 for a box of 10 liqui-paks, each pre-dosed for children older than 1 year, according to a Jan. 26 release. The product is sold at Michigan and Missouri retail stores and online. While FDA revises the pediatric cough/cold rules, Chamberlain claims honey is a safe alternative (1"The Tan Sheet" Oct. 6, 2008, p. 3)

People In Brief

Perrigo promotes in pricing, planning

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts